UNSPSC 51333102: Etazolate

This classification denotes an anxiolytic with the molecular formula C14H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I89Y79062L, chemically known as 1h-pyrazolo(3,4-b)pyridine-5-carboxylic acid, 1-ethyl-4-((1-methylethylidene)hydrazino)-, ethyl ester but generally known as etazolate, which bears US NIH Compound Identifier 3277. European Medicines Agency schedules Etazolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07267MIG.

UNSPSC 51333102 Etazolate is a Commodity code that in practice captures pharmaceutical products and related systems procured by state and local governments for emergency response, community health, and multi-jurisdictional pharmacy benefit programs. Recent state and local solicitations under this code show demand for naloxone units and drug deactivation systems, direct-to-manufacturer prescription fulfillment capabilities, and generic multi-source pharmaceuticals distributed through authorized wholesaler networks. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). State and local governments are buying finished pharmaceutical inventory, pharmacy benefit program infrastructure, and supply-chain management services rather than active pharmaceutical ingredients alone.

Geographic activity spans Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving participating jurisdictions across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date discrepancy in source); Texas HHS Commission's Request for Information HHS0017013, posted April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to improve prescription fulfillment efficiency; and Minnesota's MMCAP Request for Proposal S1070000015802, posted January 20, 2026, seeking generic multi-source pharmaceutical manufacturers with pricing submissions due March 26, 2026 and contract effectiveness July 1, 2026. Vendors responding to these opportunities must hold required insurance coverage, comply with Drug Supply Chain Security Act standards and FDA requirements, and demonstrate EDI and wholesaler integration capabilities.